These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 38634898)

  • 1. Real-world prevalence of microsatellite instability testing and related status in women with advanced endometrial cancer in Europe.
    Kelkar SS; Prabhu VS; Zhang J; Ogando YM; Roney K; Verma RP; Miles N; Marth C
    Arch Gynecol Obstet; 2024 Jun; 309(6):2833-2841. PubMed ID: 38634898
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discordant loss of mismatch repair proteins in advanced endometrial endometrioid carcinoma compared to paired primary uterine tumors.
    Ta RM; Hecht JL; Lin DI
    Gynecol Oncol; 2018 Dec; 151(3):401-406. PubMed ID: 30340772
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Real-world treatment patterns and clinical outcomes from a retrospective chart review study of patients with recurrent or advanced endometrial cancer who progressed following prior systemic therapy in Europe.
    Zhang J; Kelkar SS; Prabhu VS; Qiao Y; Grall V; Miles N; Marth C
    BMJ Open; 2024 Apr; 14(4):e079447. PubMed ID: 38569701
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical patterns and genomic profiling of recurrent 'ultra-low risk' endometrial cancer.
    Stasenko M; Feit N; Lee SSK; Shepherd C; Soslow RA; Cadoo KA; Alektiar K; Da Silva EM; Martins Sebastião AP; Leitao MM; Gardner G; Selenica P; Abu-Rustum NR; Weigelt B; Mueller JJ
    Int J Gynecol Cancer; 2020 Jun; 30(6):717-723. PubMed ID: 32376737
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment patterns and real-world clinical outcomes in patients with advanced endometrial cancer who are microsatellite instability (MSI)-high or are mismatch repair deficient (dMMR) in the United States.
    Kelkar SS; Prabhu VS; Corman S; Odak S; Rusibamayila N; Macahilig C; Orlowski R; Duska L
    Gynecol Oncol; 2023 Feb; 169():154-163. PubMed ID: 36344294
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of mismatch-repair/microsatellite instability-discordant endometrial cancers.
    Riedinger CJ; Esnakula A; Haight PJ; Suarez AA; Chen W; Gillespie J; Villacres A; Chassen A; Cohn DE; Goodfellow PJ; Cosgrove CM
    Cancer; 2024 Feb; 130(3):385-399. PubMed ID: 37751191
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical outcomes of patients with POLE mutated endometrioid endometrial cancer.
    Stasenko M; Tunnage I; Ashley CW; Rubinstein MM; Latham AJ; Da Cruz Paula A; Mueller JJ; Leitao MM; Friedman CF; Makker V; Soslow RA; DeLair DF; Hyman DM; Zamarin D; Alektiar KM; Aghajanian CA; Abu-Rustum NR; Weigelt B; Cadoo KA
    Gynecol Oncol; 2020 Jan; 156(1):194-202. PubMed ID: 31757464
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of immunotherapy in advanced and recurrent MMR deficient and proficient endometrial carcinoma.
    Di Dio C; Bogani G; Di Donato V; Cuccu I; Muzii L; Musacchio L; Scambia G; Lorusso D
    Gynecol Oncol; 2023 Feb; 169():27-33. PubMed ID: 36493574
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular markers in recurrent stage I, grade 1 endometrioid endometrial cancers.
    Moroney MR; Davies KD; Wilberger AC; Sheeder J; Post MD; Berning AA; Fisher C; Lefkowits C; Guntupalli SR; Behbakht K; Corr BR
    Gynecol Oncol; 2019 Jun; 153(3):517-520. PubMed ID: 30910249
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epigenetic silencing of MLH1 in endometrial cancers is associated with larger tumor volume, increased rate of lymph node positivity and reduced recurrence-free survival.
    Cosgrove CM; Cohn DE; Hampel H; Frankel WL; Jones D; McElroy JP; Suarez AA; Zhao W; Chen W; Salani R; Copeland LJ; O'Malley DM; Fowler JM; Yilmaz A; Chassen AS; Pearlman R; Goodfellow PJ; Backes FJ
    Gynecol Oncol; 2017 Sep; 146(3):588-595. PubMed ID: 28709704
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ovarian endometrioid adenocarcinoma: incidence and clinical significance of the morphologic and immunohistochemical markers of mismatch repair protein defects and tumor microsatellite instability.
    Aysal A; Karnezis A; Medhi I; Grenert JP; Zaloudek CJ; Rabban JT
    Am J Surg Pathol; 2012 Feb; 36(2):163-72. PubMed ID: 22189970
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Comprehensive assessment of mismatch repair and microsatellite instability status in molecular classification of endometrial carcinoma].
    Liu Y; Wang YX; Sun XJ; Ting X; Wu R; Liu XD; Liu CR
    Zhonghua Fu Chan Ke Za Zhi; 2023 Oct; 58(10):755-765. PubMed ID: 37849256
    [No Abstract]   [Full Text] [Related]  

  • 13. Clinicopathologic Significance of Mismatch Repair Defects in Endometrial Cancer: An NRG Oncology/Gynecologic Oncology Group Study.
    McMeekin DS; Tritchler DL; Cohn DE; Mutch DG; Lankes HA; Geller MA; Powell MA; Backes FJ; Landrum LM; Zaino R; Broaddus RD; Ramirez N; Gao F; Ali S; Darcy KM; Pearl ML; DiSilvestro PA; Lele SB; Goodfellow PJ
    J Clin Oncol; 2016 Sep; 34(25):3062-8. PubMed ID: 27325856
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Frequent CTNNB1 or PIK3CA Mutations Occurred in Endometrial Endometrioid Adenocarcinoma With High Levels of Microsatellite Instability and Loss of MSH2/MSH6 Expression.
    Huang HN; Kuo CW; Lin MC; Mao TL; Kuo KT
    Appl Immunohistochem Mol Morphol; 2020 Apr; 28(4):284-289. PubMed ID: 30789355
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Multi-cohort Study of the Prognostic Significance of Microsatellite Instability or Mismatch Repair Status after Recurrence of Resectable Gastric Cancer.
    An JY; Choi YY; Lee J; Hyung WJ; Kim KM; Noh SH; Choi MG; Cheong JH
    Cancer Res Treat; 2020 Oct; 52(4):1153-1161. PubMed ID: 32599987
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mismatch-repair deficiency, microsatellite instability, and lynch syndrome in ovarian cancer: A systematic review and meta-analysis.
    Mitric C; Salman L; Abrahamyan L; Kim SR; Pechlivanoglou P; Chan KKW; Gien LT; Ferguson SE
    Gynecol Oncol; 2023 Mar; 170():133-142. PubMed ID: 36682091
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment patterns and real-world clinical outcomes in patients with advanced endometrial cancer that are non-microsatellite instability high (non-MSI-high) or mismatch repair proficient (pMMR) in the United States.
    Kelkar SS; Prabhu VS; Zhang J; Corman S; Macahilig C; Rusibamayila N; Odak S; Duska LR
    Gynecol Oncol Rep; 2022 Aug; 42():101026. PubMed ID: 35800987
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Universal endometrial cancer tumor typing: How much has immunohistochemistry, microsatellite instability, and MLH1 methylation improved the diagnosis of Lynch syndrome across the population?
    Kahn RM; Gordhandas S; Maddy BP; Baltich Nelson B; Askin G; Christos PJ; Caputo TA; Chapman-Davis E; Holcomb K; Frey MK
    Cancer; 2019 Sep; 125(18):3172-3183. PubMed ID: 31150123
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Detection of DNA mismatch repair (MMR) deficiencies by immunohistochemistry can effectively diagnose the microsatellite instability (MSI) phenotype in endometrial carcinomas.
    McConechy MK; Talhouk A; Li-Chang HH; Leung S; Huntsman DG; Gilks CB; McAlpine JN
    Gynecol Oncol; 2015 May; 137(2):306-10. PubMed ID: 25636458
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Highly Sensitive Microsatellite Instability and Immunohistochemistry Assessment in Endometrial Aspirates as a Tool for Cancer Risk Individualization in Lynch Syndrome.
    Canet-Hermida J; Marín F; Dorca E; Dueñas N; Costas L; Salinas M; Velasco À; Peremiquel-Trillas P; Paytubi S; Ponce J; Fernández S; Martínez JM; Cárdenas L; Taltavull A; Alemany L; Meléndez C; Oliveras G; Vidal A; Capellá G; López-Bonet E; Brunet J; Matias-Guiu X; Pineda M
    Mod Pathol; 2023 Jul; 36(7):100158. PubMed ID: 36918055
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.